Unknown OBSERVATIONAL NCT00973505

CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI) (AI-CYP19)

Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)

Sponsor: Korea University

Conditions Arthralgia Arthritis Breast Neoplasms Genetic Polymorphism

Interventions Aromatase Inhibitor(Femara or Arimidex)

Updated 10 times since 2017 Last updated: Sep 8, 2009 Started: Mar 31, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00973505, this observational or N/A phase trial focuses on Arthralgia and Arthritis and remains ongoing. Sponsored by Korea University, it has been updated 10 times since 2009, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Unknown
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Dec 2021 — Jul 2024 [monthly]

Unknown Status
Jan 2021 — Dec 2021 [monthly]

Unknown Status

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Unknown Status
May 2018 — Nov 2020 [monthly]

Unknown Status
Apr 2018 — May 2018 [monthly]

Unknown Status

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Unknown Status NA
Jan 2017 — Aug 2017 [monthly]

Unknown Status NA

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea University
Korea University Anam Hospital

Data source: Korea University Anam Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea